Sigachi Industries Ltd

- The company has issued share warrants totaling INR 286.45 crores for capital expenditure and acquisitions, including INR 160 crores for acquisition and expansion of API facility (Trimax Bio Sciences), INR 50 crores for Dahej and Jhagadia expansion, and INR 22 crores for augmentation of Hyderabad unit. - These share warrants are issued to a group of investors including promoters, with a standard 18-month conversion term. - Additional funds are planned through retained earnings, further equity infusion, or debt. - Promoter pledging of shares was done solely to raise money for further investment, which was infused back into the company. - The company is optimistic about using a mix of retained earnings, equity, and debt to fund ongoing INR 200 crores capex over FY24 and FY25. - There is no explicit recent announcement of fresh debt fundraise, but a mix of funding methods is contemplated.

- Total planned capex is around INR 200 crores: INR 100 crores in FY24 and INR 100 crores in FY25. - INR 160 crores out of this is allocated towards acquisition and expansion of the API facility, specifically Trimax Bio Sciences at Raichur. - INR 50 crores allocated for expansion of Dahej and Jhagadia units. - INR 22 crores planned for augmentation of the Hyderabad unit. - Additional funds raised through share warrants (INR 286.45 crores issued) and other sources like retained earnings or debt. - The capex is expected to take time to capitalize and show results due to necessary validations and commissioning. - CCS (Croscarmellose Sodium) project capex delayed due to environmental clearance but expected to be deployed by March, with commissioning over next 18 months. - MCC plant capacity expansion underway, increasing capacity from 14,000 to 21,000 metric tons, expected to start sales from end of February.

- Sigachi Industries aims for around 30% revenue growth for FY24-25 due to capex and API segment expansion. - Historically, the company has grown at a 25% CAGR, with expectations of slightly higher growth in current fiscal. - Capacity expansion from 14,000 tons to 21,000 tons for MCC will boost production volumes and revenue. - The company expects to surpass INR 600 crores in sales around FY25-26, driven by expanded capacity and API business. - MCC quantity increased by 12% YoY (from 9,851 MT to 11,036 MT) with current utilization about 90-95%. - Growth drivers include strong pharma demand for excipients (MCC/CCS) and increased contribution from API manufacturing. - API segment targeted to achieve positive EBITDA margins and contribute substantially to overall revenue mix. - O&M and subsidiaries like Sigachi US are also contributing to growth, with O&M revenue rising from INR 13.3 crores to INR 35 crores over three years.

- Sigachi Industries expects to achieve around 30% sales growth in FY24-25 driven by capex and new product launches like CCS and API segment. - The company aims to surpass INR 600 crores turnover by the financial year 2025-26, potentially mid-year or by year-end. - EBITDA margins are targeted to improve, especially from the API vertical, with a positive contribution of around 20% expected over two years. - The expanded MCC capacity and API acquisition will contribute to margin expansion and volume growth. - The company has a history of 25% CAGR and expects accelerated growth due to capacity expansions and regulatory approvals for APIs. - Operational efficiencies and economies of scale from ongoing capex are expected to improve profitability and EPS over the medium term.

- The transcript does not explicitly mention the current or expected order book or pending orders for Sigachi Industries Limited. - However, it indicates strong demand with production of 11,036 metric tons out of an expected capacity of around 14,000 metric tons (with near 90% utilization as per management). - The company is confident about growth prospects, projecting around 30% growth for FY 2024-25 driven by capex and new product lines like API and CCS. - Expansion projects including MCC capacity expansion and CCS project commissioning are expected to contribute to increased sales and order fulfillment in the coming quarters. - The management expects turnover to cross INR 600 crores by mid to end of FY 2025-26, indicating healthy order flow and visibility. - API segment acquisition (Trimax) also contributes to potential order growth from regulated markets in the future.